^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Xpovio (selinexor)

    i
    Other names: KPT-330, KPT-330-003, SINE KPT-330, KPT330, KPT 330, ATG-010, ONO-7705, ONO 7705, ATG010, ATG 010, ONO7705
    Company:
    Antengene, FORUS Therap, Jiangsu Hansoh Pharma, Karyopharm, Menarini, NeoPharm
    Drug class:
    XPO1 inhibitor
    Related drugs:
    6d
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna
    6d
    SEATTLE: Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=75, Active, not recruiting, iOMEDICO AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Xpovio (selinexor) • dexamethasone
    12d
    GEMS-001: A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes (clinicaltrials.gov)
    P=N/A, N=114, Completed, University Health Network, Toronto | Active, not recruiting --> Completed
    Trial completion
    |
    Xpovio (selinexor)
    13d
    Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL. (PubMed, Tumori)
    The XPO1 inhibitor KPT-330 exerts anti-cancer effects through stabilizing p53 and inhibiting the PI3K-AKT pathway, providing a molecular basis for DLBCL treatment. We may provide a potential promising combination therapy for the treatment of DLBCL with p53 mutations.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
    |
    TP53 mutation
    |
    Xpovio (selinexor)
    15d
    TOUCH: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=56, Terminated, Antengene Corporation | Active, not recruiting --> Terminated; Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study
    Trial termination
    |
    carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • ifosfamide • oxaliplatin • etoposide IV • Xpovio (selinexor)
    27d
    Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer. (PubMed, Cells)
    Inhibition of XPO1 with selective inhibitors of nuclear export (SINE) compounds, including selinexor, has demonstrated the ability to restore nuclear localization and function of these proteins, thereby enhancing cellular sensitivity to DNA-damaging agents, kinase inhibitors, and immunotherapies. In preclinical NSCLC models, XPO1 inhibition has shown efficacy both as monotherapy and in combination strategies, with particular promise in KRAS- and EGFR-driven tumors. This review explores the role of XPO1 in NSCLC biology and therapy resistance, the rationale for targeting nuclear export, and the current landscape of XPO1-directed clinical development in lung cancer.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • XPO1 (Exportin 1)
    |
    Xpovio (selinexor)
    28d
    XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis. (PubMed, Cell Commun Signal)
    Selinexor and azacitidine offer a promising strategy to overcome therapeutic resistance and improve outcomes in TET2/RHOA-mutated PTCL, supporting further clinical evaluation.
    Journal • IO biomarker
    |
    TET2 (Tet Methylcytosine Dioxygenase 2) • JAK3 (Janus Kinase 3) • RHOA (Ras homolog family member A) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    TET2 mutation • STAT3 mutation
    |
    azacitidine • Xpovio (selinexor)
    29d
    Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets)
    1m
    NCI-2020-09704: Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Mayo Clinic | Trial completion date: Aug 2027 --> Jun 2026
    Trial completion date
    |
    Xpovio (selinexor)
    1m
    Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration. (PubMed, Front Immunol)
    CRM1 inhibition by Selinexor re-establishes nuclear PHD2 residency, increases the degradation of HIF-1α in hypoxia, abrogates P-gp-mediated lysosomal anthracycline trapping, and confers potent in-vitro and in-vivo chemosensitization. These data provide mechanistic rationale for integrating Selinexor into salvage regimens for R/R-AML.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    Xpovio (selinexor)
    1m
    Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    azacitidine • Xpovio (selinexor)
    2ms
    XPORT-MM-031: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma (clinicaltrials.gov)
    P3, N=117, Active, not recruiting, European Myeloma Network B.V. | Recruiting --> Active, not recruiting | N=222 --> 117
    Enrollment closed • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Xpovio (selinexor) • dexamethasone • pomalidomide • Empliciti (elotuzumab)